Studies in European and US farming populations have documented major reductions in asthma prevalence in offspring of mothers exposed to microbial breakdown products present in farm dusts and unprocessed foods. This was associated with enhancement of innate immune competence in the offspring. We sought to (i) identify a safe therapeutic that would reproduce these immunomodulatory effects in a murine model, (ii) elucidate underlying mechanism(s)-of-action, and (iii) develop a scientific rationale for progressing this approach to human trials. We demonstrate in mice that maternal treatment during pregnancy with the microbial-derived immunomodulator OM85, which has been used clinically in adults and children in Europe for >30 years for bolstering resistance to infection-associated airways inflammation, markedly reduces the susceptibility of the offspring of treated mothers to development of experimental atopic asthma. We identify bone marrow precursors of the dendritic cell populations responsible for airway mucosal immune surveillance as the primary targets for the asthma-protective effects of maternal OM85 treatment in the offspring.
INTRODUCTION
A series of prospective birth cohort studies on the children of European traditional farming families 1, 2 , now replicated in US studies contrasting Amish and Hutterite farming populations 3 , have identified striking asthma-protective properties of oral and inhalation exposure to benign microbial stimuli present in dusts from farm barns. The target for these exposures in the offspring appears to be the innate immune system, and involves modulation of both immunoregulatory and effector cell function(s) [3] [4] [5] [6] resulting in markedly reduced susceptibility to the asthma-promoting effects of common respiratory allergies. The temporal window during which these environmental stimuli exert their immunomodulatory effects spans the period when the developing immune system is undergoing postnatal functional maturation, but susceptibility to these effects also appears particularly high during prenatal development as demonstrated by the strong impact of maternal microbial exposures during pregnancy on ensuing asthma resistance in their offspring 1, 7 .
We posited that if these benign environmental exposure effects could be reproduced by a therapeutic that could be safely administered during pregnancy, then this could open up novel possibilities for primary prevention of asthma. With this in mind we have recently completed a proof-of-concept study in pregnant mice with a microbial-derived therapeutic product OM85, which has been in widespread use in Europe in infants and adults for >30 years for boosting resistance to airways inflammation and attendant wheezing symptoms associated with lower respiratory infections [8] [9] [10] [11] [12] . In preliminary investigations to establish the safety of OM85 use during pregnancy we demonstrated that maternal treatment with this agent enhanced homeostatic control of innate immune and inflammatory functions in gestational tissues at baseline and in the face of challenge with microbial pathogens including live influenza infection and the bacterial mimic LPS. Specifically, OM85 treatment attenuated inflammatory symptoms (which are typically exaggerated during pregnancy) and protected against fetal growth restriction and/or pregnancy termination which can follow maternal infection 13 . In the study presented here we focus on the effects of maternal OM85 treatment during healthy pregnancy on the immunocompetence of offspring during the postnatal weanling period when immune functions are typically developmentally compromised. In this regard, we focus on the effects of maternal OM85 treatment on the capacity of offspring to regulate airways inflammatory responses associated with development of experimental atopic asthma during the weanling period, which in humans represents the age range at highest risk
for initiation of what can be life-long asthma 14 .
RESULTS

Experimental model of atopic asthma in sensitized weanling mice: study rationale
For this study we utilized an experimental system developed for induction of Th2-associated cell-mediated inflammation in the conducting airway mucosa in adult rodents, as a model for the main lesional site in human asthma. Additional (albeit less extensive) inflammation also develops in peripheral lung tissue, but the relative contribution of this to airflow limitation in the asthmatic state is uncertain. The principal features of this model, focusing mainly on the airway mucosa, are illustrated in Fig. S1A . Aeroallergen delivered to the airways of presensitized animals via large-droplet aerosol is captured by resident mucosal dendritic cells (DC) that are functionally quiescent in the steady-state (as marked by low-modest IAIE expression) and are specialised for antigen sampling only, which they subsequently transport to airway draining lymph nodes (ADLN) for presentation to allergen-specific T-memory cells [15] [16] [17] . The resultant T-cell response generates a mixture of T-effector-memory (T m eff) and T-regulatory (Treg) cells in proportions determined via DC programming. Representatives of these populations traffic back to the airway mucosa, where they encounter resident mucosal DC which have recently acquired aeroallergen, and bidirectional interactions between these three cell populations in situ determine the intensity and duration of the ensuing T-cell dependent inflammatory response within the airway mucosa 18, 19 . In particular, the capacity for local activation of incoming T m effs is limited via the suppressive effects of Tregs on surface IAIE and CD86 expression by mucosal conventional DC (cDC) 15, [19] [20] [21] .
The principal DC population involved comprises the network of cDC within the airway mucosa, that are responsible for the major aspects of local immune surveillance 15 .
Plasmacytoid DC (pDC) have also been implicated in this process 22 , particularly in relation to pathogen surveillance 23 . The airway mucosal cDC population has the property of uniquely rapid turnover in the steady-state with 85% of the resident population turning over every ~24
hours, being continuously depleted by migration of antigen-bearing cells to ADLN and simultaneously replenished via incoming precursors recruited from bone marrow 24 . This orderly and highly dynamic process is rapidly accelerated during airway challenge events, during which cDC numbers can expand markedly within the airway epithelium and ADLN 15, [25] [26] [27] . This airway mucosal cDC network is developmentally compromised in immature humans 28, 29 and experimental animals 30, 31 , and this partially explains the high risk of respiratory infections and aeroallergen sensitization associated with the infant period 32 . Our hypothesis underlying this murine study is that maternal OM85-treatment during pregnancy can enhance the functional maturation of this mucosal immune surveillance system in their offspring, and as a result reduce susceptibility to initiation of inflammatory airway disease during the high-risk early postnatal period.
To test this hypothesis, we have utilised a variant of the above mentioned asthma model, modified from earlier studies assessing farm-related exposures 33 , involving sensitization of 21 day old weanling BALB/c mice to ovalbumin (OVA) employing a prime-boost schedule followed by subsequent airways challenge with aerosolised OVA (Fig. S1B, C) . Details of the ensuing response are discussed below.
Aeroallergen-induced cellular response in the airways: baseline characteristics
Sensitized animals display high levels of OVA-specific serum IgE 24 hours following repeated OVA-aerosol challenge (Fig. 1A) . The challenged animals display gross hypertrophy of ADLN involving in particular T-cells (see below), which is accompanied by intense inflammatory cell infiltration into the airways encompassing eosinophils, neutrophils and lymphocytes detectable by BAL (Fig. 1B) , increased levels of Th2 cytokines in lung homogenates (not shown), and airways hyperresponsiveness (AHR) manifesting as increased airways resistance (R aw ) to methacholine (MCh; Fig. 1C ).
Further characterization of the phenotype of the cellular response within the airways compartment by multi-colour flow cytometry (see Methods for gating strategies) revealed significant increases in the total cellularity of parathymic and mediastinal ADLN and trachea, with no observable difference in peripheral lung (Fig. S1D ). This cellular response was dominated by changes in the CD3 + T-cells ( Fig. S1E ) and especially the CD4 + T-cell compartment (Fig. S1F ). These changes in particular involved increases in the numbers ( observed, accompanied by a large increase within trachea and a smaller (but significant) increase in peripheral lung tissues (Fig. 1G) (Fig. 1J, K) . Consecutive aerosol challenges of pre-sensitised mice induces a minor response in pDC in peripheral lung only (Fig. 1K) , in contrast to a significant influx of both cDC subsets across all airways tissues sampled, in particular the tracheal mucosa and its ADLN where numbers of these cells displayed a logfold increase (Fig. 1L, M) . Characterisation of cDC based on expression levels of surface IAIE demonstrated marked enhancement in expression intensity across the entire cDC population within the trachea following challenge (Fig. 1N, O) . This observation is consistent with allergen-driven functional maturation in situ of these cells from strict antigen-sampling to antigen-presentation phenotype as previously observed 15, 16 , and this provides a plausible mechanism for local activation of T m effs within the mucosa during repeated challenge (Fig.   1D, F) . In parallel, ADLN displayed modest IAIE upregulation in the CD103 + subset, while both subsets remained at baseline in the peripheral lung (Fig. 1N, O) . Furthermore, upregulation of pDC IAIE expression occurred both in ADLN and peripheral lung (Fig. 1P) . (Fig. 1Q) .
Role of the bone marrow in the experimental asthma response
The granulocytic and DC subsets identified above as participants in the airways response to aerosol challenge in sensitized mice are derived from bone marrow, and we posited that (as inferred from earlier studies on eosinophils in aeroallergen challenged human asthmatics 38 ) the dynamic changes detailed in these populations in our murine asthma model above should be mirrored by changes in respective bone marrow precursor populations.
The scheme in Fig. S2 summarizes current understanding of the interrelationships between relevant bone marrow progenitor compartments in the development pathway leading to production of granulocytes, pDC and cDC. We assessed the impact of repeated challenge with aeroallergen on the size of relevant compartments at or beyond the myeloid precursor (MP) stage, employing multicolour flow cytometry, targeting the markers shown. These analyses ( Fig. 2A-D ) demonstrate firstly that early myeloid precursor compartments up to and including the granulocyte-macrophage progenitor (GMP) population, which are a major source of both DC and granulocyte populations 39, 40 , and the macrophage-dendritic cell progenitor (MDP) compartment which is committed to pDC and cDC production [41] [42] [43] , expand significantly in response to repeated aeroallergen challenge of sensitized animals. This finding is consistent with the data shown in Fig. 1 , demonstrating the buildup of these populations in the challenged airways. Beyond this stage the cDC compartment appeared reduced relative to baseline ( 
Treg function in offspring as a potential target for maternal OM85 treatment effects
Previous studies from our lab and others have identified mucosal homing Tregs as a potential target for OM85-mediated treatment effects in adult non-pregnant 44, 45 and pregnant 13 animals, prompting an initial focus on this population. We accordingly phenotyped the T-cell response within the airways compartment using multi-colour flow cytometry. The magnitude of the overall CD4 + T-cell response to OVA aerosol was reduced in the treatment group, particularly in the tracheal mucosa ( Maternal OM85 pre-treatment modulates the functional phenotype of airway-associated
DC populations in offspring
The accumulation of cDC in airway-associated tissue compartments in response to airways challenge was generally reduced in the treated group, and these differences were statistically significant for CD103 + cDC in the trachea, and for CD11b + cDC in ADLN and lung ( Fig. 5A , B). However, the most notable finding related to cDC maturational status as measured by surface IAIE expression, which was reduced at baseline in both CD103 + and CD11b + subsets in ADLN (Fig. 5C ). Moreover, the antigen-induced surge in IAIE expression levels on both subsets in the rapidly turning over cDC population in the tracheal mucosa, which is a hallmark of functional activation of these cells, was likewise attenuated (Fig. 5D ). This contrasted with the picture in the peripheral lung ( Fig. 5E ), which is dominated by cDC populations with much longer half-lives, and which displayed minimal upregulation of IAIE in response to challenge. However as noted above, aerosol challenge does elicit a small but significant increase in pDC in peripheral lung tissue, and this response was attenuated in the treated group (Fig. 5F , G). We also screened the groups for treatment effects on the rare inflammatory DC subset in airway tissues, however none were detected (data not shown).
Offspring bone marrow as the primary target for maternal OM85 treatment effects
The final series of experiments tested the hypothesis that maternal OM85 treatment mediated effects on cellular immune function(s) in offspring respiratory tract tissues in this model may be associated with upstream effects on relevant precursor populations in bone marrow. Fig. 6 directly compares the aeroallergen-induced bone marrow responses of offspring from treated versus untreated mothers. Firstly, while baseline output of pre-cDC and cDC was comparable between groups, there were small but significant increases in the resting GMP and MDP populations in the control offspring from treated mothers (Fig. 6C, D) . However, the major treatment-associated differences were revealed by aeroallergen challenge, notably a consistent attenuation of the expansion in all precursor compartments spanning the MP-MDP stages which was observed in the challenged offspring from untreated mothers (Fig. 6A-D) .
Secondly, at the end of this developmental spectrum, the post challenge depletion of bone marrow cDC reserves that occurs in the offspring of untreated mothers was significantly attenuated (Fig. 6E, F) , consistent with the reduced draw on this pool resulting from reduced recruitment to airway mucosa and ADLN in the OM85-treated group (Fig. 5A, B) .
It is additionally pertinent to note that expression levels of IAIE on cDC were reduced in the treated group both at baseline and in particular post-challenge (Fig. 6G) , suggesting maintenance of a more tightly regulated/quiescent functional state, mirroring the picture seen for trachea and ADLN cDC in Fig. 5 . A similar pattern was also observed in relation to the bone marrow pDC reservoir (data not shown).
Maternal OM85 treatment effects at earlier ages
The data above pertains to animals sensitized at 3 weeks and challenged/sacrificed at 6
weeks. In the studies presented in Fig. 7 , we assessed the extent to which treatment effects on DC populations were demonstrable at younger ages. Looking firstly at age 3 weeks, we observed that the offspring of OM85-treated mothers displayed higher numbers CD11b + and CD103 + cDC in lung tissue at baseline (Fig. 7A, B ) and higher levels of attendant IAIE expression (Fig. 7C) , consistent with treatment-mediated acceleration of postnatal maturation of DC networks in the respiratory tract. In a preliminary experiment we also compared total cDC yields in GM-CSF-driven bone marrow cultures derived from the same animals, and the increased yields from the treated group (Fig. 7D ) again point to the marrow as the likely primary site of action of maternal OM85 treatment.
To further extend this finding, we characterised the progenitor pool within freshly harvested fetal bone marrow at 18.5 days gestation, 24 hours following the last maternal OM85 oral dose. The marked increase in total bone marrow cDC (Fig. 7E ) accompanied by parallel expansion in the upstream MDP compartment in the treated group (Fig. 7F) is consistent with the conclusion that the bone marrow is a direct target for OM85 treatment effects.
OM85-mediated attenuation of the responsiveness of bone marrow DC precursors to environmental inflammatory stimuli: validation of OM85 treatment effects in an independent inflammatory model
In the experiments illustrated in Fig. 8 we cultured bone marrow from 6-week old offspring of OM85-treated/untreated mothers in GM-CSF-enriched medium for 7 days, adding the archetypal pro-inflammatory agent bacterial LPS to half the cultures for the last 24 hours.
Comparison of resultant activation levels of cDC by surface expression of IAIE ( state. We also demonstrate for the first time that these rapid changes in the population dynamics of cDC in the challenged airways of sensitized animals are accompanied by concomitant depletion of committed cDC from bone marrow, and parallel (presumably compensatory) expansion of upstream multipotent precursor compartments.
We further demonstrate that susceptibility to this aeroallergen-induced asthma-like response in the airways is markedly attenuated in young animals born to mothers given repeated doses of OM85 during pregnancy. Accompanying this acquired resistant state is increased capacity In this regard, we 45 and others 44 (Fig. 7A, B ) and higher cDC yields from bone marrow cultures (Fig. 7D) ; (iii) the frequency of cDC and their MDP precursors in fetal bone marrow are already increased in those from treated mothers by late gestation (Fig. 7E,   F ). However, the strongest evidence for treatment related effects at the DC precursor stage comes from the studies on cDC from 6-week old GM-CSF-driven 7-day bone marrow cultures ( Fig. 8) . The introduction of the archetypal pro-inflammatory stimulus bacterial LPS for the final 24 hours of these cultures triggers ultra-high expression on cDC from untreated controls of both IAIE and CD86, at levels likely to result in potentially pathologic T-cell hyperstimulation. However, this upregulation was more tightly controlled in cDC from offspring of treated mothers, suggesting enhanced capacity to maintain homeostasis and avoid bystander damage to host tissues during immunoinflammatory responses to environmental stimuli.
We acknowledge several limitations to this study. Firstly, we have not addressed the question of whether OM85 treatment influences susceptibility to primary allergic sensitization to inhalant allergens, and this merits future investigation, given that this process has also been shown to be controlled by ADLN-derived Tregs 46 . Secondly, we have no information on the mechanism of transmission of orally delivered OM85-associated signals to the bone marrow.
Earlier studies from our group 45 and others 44 have demonstrated local activation of both Tcells and myeloid cells in the gut wall and associated lymphoid tissues following OM85 feeding, and it is possible that trafficking of representatives of either or both of these populations, or transmission of soluble signals generated at these sites, may be involved.
Likewise, information on the gene target(s) in fetal bone marrow DC progenitors is not available, and will be the subject of future studies, along with possible effects on fetal thymus. Additionally, OM85 dosing of mothers in this study spanned only the second half of gestation, and future studies need to investigate the impact of extending feeding to earlier stages.
Our goal in this study was to provide a scientific rationale for subsequent use of OM85 during pregnancy in human mothers whose progeny are at risk of postnatal development of persistent atopy and/or asthma. The prime initial candidates for therapy in this regard are atopic asthmatic mothers 47, 48 . The severity of asthma symptomatology in this group is exaggerated during pregnancy [49] [50] [51] , likely as a consequence of the generalized Th2-skewing of immune functions associated with the pregnant state, and asthma exacerbations during pregnancy further increase asthma risk for their offspring 52 . Moreover, susceptibility to respiratory infections exemplified by influenza virus and its associated symptom severity is likewise increased during pregnancy 53, 54 , and the latter (along with bacterial infections) is a risk factor for fetal growth restriction 55 which in turn is associated with increased risk for postnatal development of a range of non-communicable diseases including asthma 56, 57 . In this regard, our forerunner studies on OM85 use in pregnant mice have demonstrated strong protection against the effects of pathogen-associated challenge during pregnancy employing high dose LPS or live influenza, both with respect to preservation of pregnancy per se, and maintenance of normal maternal weight gain and associated fetal growth trajectories 13 . In this system the principal treatment effect of OM85 involved selective attenuation within gestational tissues of the intensity of the pro-inflammatory (particularly TNFα/IL-1/IL-6) components of the myeloid innate immune response to pathogen, with parallel preservation of vigorous Type 1 IFN-associated host defense networks 13 . Moreover, we 45 and others 44 have also previously demonstrated marked attenuation of airways inflammation in OM85-treated adult animals in models of experimental atopic asthma. On this basis, it can be argued that OM85 use during pregnancy has potential direct short-term benefits to mothers, as well as long-term benefits to their offspring in regards to reduced susceptibility to asthma development. The latter may also include enhanced resistance to early postnatal respiratory infections, given the OM85-associated effects demonstrated above on increased airway mucosal cDC numbers and IAIE expression at baseline in 3-week old weanlings, and studies are in progress to test this possibility.
A series of additional steps are required before progression to human trials with OM85 in pregnancy. The first involves an independent assessment by regulators of relevant safety issues. In this regard there is a wide body of data available on safe use during pregnancy in experimental animals, including our own 13 . Direct human safety data for pregnancy is not presently available. However, there is a >30-year history of safe use in non-pregnant adult humans and children down to age 6 months, and this has proven sufficient for relevant US 58 (NIH) and Australian 59 (NHMRC) authorities to endorse and publicly fund multicenter clinical trials in infants, targeting protection against wheezing symptoms (including those associated with early infections) and subsequent asthma development. In this regard, it is evident that airways inflammation associated with infections and inhalant allergy act in synergy to drive asthma pathogenesis during childhood 32 , and moreover that the earlier these episodic inflammatory events commence after birth, the greater is the risk for subsequent asthma [60] [61] [62] . This provides a compelling argument for development of protective therapeutic strategies that can reduce susceptibility to either or both of these environmental stressors, from birth onwards, and the possibility that this may be achievable prenatally with a readily available therapeutic such as OM85 merits further detailed investigation.
MATERIALS AND METHODS
Study Design
The objective of this pre-clinical BALB/c study was to identify a safe therapeutic immune modulating agent that could replicate the microbial-induced protection of offspring from allergic asthma observed on European farms and elucidate the underlying mechanism(s)-ofaction promoting protection. We hypothesised that maternal OM85 treatment during gestation would alter the responsiveness and functional maturation of T cell and dendritic cell populations within the airways of antigen-sensitised and aerosol challenged offspring, thereby reducing offspring susceptibility to experimental asthma. However, observations made in the bone marrow revealed that the airways response may be secondary to upstream attenuation of the bone marrow compartment following maternal OM85 treatment.
Differential cell counts, passive cutaneous anaphylaxis assays, airways hyperresponsiveness, flow cytometry and in vitro cell culture was used in combination to characterise the systemic response within offspring. Passive cutaneous anaphylaxis in vivo assays were performed using Sprague Dawley rats and all other in vivo and in vitro experiments were performed using BALB/c mice. Pregnant mice were selected at random for OM85 (400mg.kg -1 ) treatment during gestation. Offspring samples size was determined based on maternal n≥6.
Experiments were independently replicated to a minimum of n=4 as outlined in corresponding figure legends. BAL differential cell counts were performed blind. All data was included unless technical issues during flow cytometry sample acquisition were deemed to have compromised the sample integrity.
Animals
Specified pathogen-free BALB/c mice and Sprague Dawley (SD) rats were obtained from the Animal Resource Centre (Murdoch, WA, Australia). All animals were housed under specified pathogen-free conditions at the Telethon Kids Institute Bioresources Facility, with a 12h:12h light-dark cycle and access to an ovalbumin-free diet and water ad libitum. All animal experiments were approved and performed in accordance with the Telethon Kids Institute Animal Ethics Committee and the NHMRC guidelines for use of animals for scientific research. In-house bred BALB/c offspring of both sexes were used in these studies.
Time-mated pregnancies
Female BALB/c mice 8 -12 weeks of age were time-mated with male studs between 8 -26 weeks of age. Male studs were housed separately in individual cages. One-to-two females were housed in an individual male cage overnight, with the presence of a vaginal plug the following morning used as an indicator of mating. The day of vaginal plug detection was designated gestation day (GD) 0.5.
Maternal OM85 treatment protocol
Based on previously optimised dosing concentrations 13, 45 , time-mated pregnant female BALB/c mice selected at random received daily feeding of lyophilised OM85 (OM Pharma, Geneva, Switzerland) reconstituted in phosphate-buffered saline (PBS) to a concentration of 400mg.kg -1 body weight for the second half of gestation (GD9.5-17.5). Controls were left untreated. All treatments were performed from a single batch of OM85 (Batch no. 1812162).
Offspring antigen sensitisation and aerosol challenge
Offspring from OM85 treated or naïve mothers were experimentally sensitised to ovalbumin 
Measurement of airway hyperresponsiveness
Airway hyperresponsiveness (AHR) to inhaled methacholine (MCh) was assessed 24 hours after a single OVA (1% weight/volume in PBS) aerosol on day 42 following presensitisation. The low-frequency forced oscillation technique (LFOT) was used to measure respiratory system input impedance (Z rs ), as determined by previously optimised protocols 63 .
Briefly, BALB/c mice were anesthetised (40% ketamine 100mg.ml -1 , 10% xylazine 20mg.ml 
Passive cutaneous anaphylaxis IgE assay
In vivo passive cutaneous anaphylaxis assays were performed using male Sprague Dawley rats >10 weeks of age. Individual BALB/c serum samples were prepared as serial 1:2 dilutions with a final sample volume of 55μl. SD rats were anaesthetised via i.p. injection of RPMI supplemented with 2mM L-glutamine, 50μM 2-β-mercaptoethanol and 5μg.ml -1 gentamycin. Wash was aspirated and 1ml of fresh RPMI-10 Complete media was added to wells. After 6 days, cells were harvested and wells washed twice with 500μl RPMI-10. Cells were centrifuged and pellets resuspended in 500µl RPMI-10 to perform total cell counts.
Following counts, cells were resuspended at a density of 1x10 6 cells.ml -1 in RPMI-10
Complete media and 1ml aliquots were re-seeded on a 24-well treated cell culture plate. After 24 hours, cells were harvested for flow cytometric phenotypic analysis. 6-week offspring.
Culture days 1-5 were as described for 3-week offspring. On day 6, cells were harvested into 
viSNE analysis
ADLN, trachea and peripheral lung FCS files, with software compensation applied, were uploaded to the Cytobank platform (Cytobank Mountain View, CA, USA) and analysed using established methods 64, 65 . The software transformed the data to arcsinh scales. Equal cell numbers were used from each FCS file. Antibodies listed as per above were used for T cell subset identification to create viSNE maps using a total of 100,000 (ADLN and peripheral lung) or 3,000 (trachea) cells per sample.
Statistical analysis
Statistical analysis and graphing was performed using GraphPad Prism (GraphPad software; version 7.0a). Statistical significance of p<0.05 was considered significant. Whitney test and presented as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
